medigraphic.com
Instituto Nacional de Salud Pública

2011, Número 5

<< Anterior Siguiente >>

salud publica mex 2011; 53 (5)


Programas internacionales para la detección del cáncer de mama

Smith RA

Idioma: Ingles.
Referencias bibliográficas: 64
Paginas: 394-404
Archivo PDF: 206.64 Kb.


RESUMEN

El beneficio de la detección temprana del cáncer de mama es el fundamento para programas alrededor del mundo que buscan reducir la morbilidad y mortalidad relacionada con este padecimiento. Estos programas abarcan desde los de tipo educativo, orientados a mujeres y profesionales de la salud, hasta programas de monitoreo organizados u oportunistas que tienen como objetivo grupos específicos de edad. Los programas modernos de mastografía tienden a seguir protocolos para estudios clínicos aleatorios, pero hay una variación en elementos clave como los grupos de edad invitados a participar, el intervalo para el monitoreo, indicadores de desempeño, y la tasa de captación. Hasta hace poco, el énfasis en la detección temprana del cáncer estaba limitado a la mastografía, pero el incremento en la incidencia y mortalidad en países de recursos bajos a medios, donde las mastografías no son asequibles, ha llevado a un renovado énfasis en el valor de los exámenes físicos. Existe un consenso en cuanto a que los programas deben estar diseñados basándose en la carga de la enfermedad y los recursos disponibles, pero incluso los países con recursos más limitados tienen oportunidades para reducir las muertes de cáncer de mama a través de un diagnóstico oportuno y un tratamiento eficaz. Los programas de detección son más eficaces cuando están organizados, y los planeadores del programa deben considerar los criterios de la OMS y la información local como bases para ajustarlos a las necesidades de la población.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Donegan WL. Introduction to the history of breast cancer. In: Donegan WL, Spratt JS, eds. Cancer of the Breast. 4th ed. Philadelphia: WB Saunders Company, 1995:1-15.

  2. O’Donnell WE, Venet L, Day E. Progress in cancer detection. I. Rationale, methods and selection of patients. CA Cancer J Clin 1958;8:186-196.

  3. Bassett LW, Gold RH, Kimme-Smith C. History of the technical development of mammography. In: Haus AG, Yaffe MJ, eds. Syllabus: A Cateorical Coursein Physics: Technical Aspects of Breast Imaging. 2nd ed. Chicago: Radiological Society of North America, 1993:9-20.

  4. Shapiro S, Strax P, Venet L. Periodic breast cancer screening in reducing mortality from breast cancer. JAMA 1971;215:1777-1785.

  5. Dodd GD. American Cancer Society guidelines on screening for breast cancer. An overview. Cancer 1992;69:1885-1887.

  6. Shapiro S. Periodic screening for breast cancer: the HIP Randomized Controlled Trial. Health Insurance Plan. J Natl Cancer Inst Monogr 1997;22:27-30.

  7. Tabar L, Duffy SW, Vitak B, Chen HH, Prevost TC. The natural history of breast carcinoma: what have we learned from screening? Cancer 1999;86:449-462.

  8. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010.

  9. Smith RA, Caleffi M, Albert US, Chen TH, Duffy SW, Franceschi D, et al. Breast cancer in limited-resource countries: early detection and access to care. Breast J 2006;12 Suppl 1:S16-26.

  10. Miles A, Cockburn J, Smith RA, Wardle J. A perspective from countries using organized screening programs. Cancer 2004;101:1201-1213.

  11. Wilson JMG, Junger G. Principles and practice of screening for disease. Geneva: World Health Organization, 1968.

  12. International Cancer Screening Network. National Cancer Institute, 2010. [Accessed January 15, 2010], Available at: http://appliedresearch.cancer.gov/icsn/.

  13. Dowling EC, Klabunde C, Patnick J, Ballard-Barbash R. Breast and cervical cancer screening programme implementation in 16 countries. J Med Screen 2010;17:139-146.

  14. Shapiro S, Venet W, Strax P, Venet L, Roeser R. Ten- to fourteenyear effect of screening on breast cancer mortality. J Natl Cancer Inst 1982;69:349-355.

  15. Tabar L, Fagerberg CJ, Gad A, Baldetorp L, Holmberg LH, Grontort O, et al. Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Lancet 1985;1:829-832.

  16. Oestreicher N, Lehman CD, Seger DJ, Buist DS, White E. The incremental contribution of clinical breast examination to invasive cancer detection in a mammography screening program. AJR Am J Roentgenol 2005;184:428-432.

  17. Smith RA, Duffy SW, Gabe R, Tabar L, Yen AM, Chen TH. The randomized trials of breast cancer screening: what have we learned? Radiol Clin North Am 2004;42:793-806, v.

  18. Tabar L, Faberberg G, Day NE, Holmberg L. What is the optimum interval between mammographic screening examinations? An analysis based on the latest results of the Swedish two-county breast cancer screening trial. Br J Cancer 1987;55:547-551.

  19. Day NE, Williams DR, Khaw KT. Breast cancer screening programmes: the development of a monitoring and evaluation system. Br J Cancer 1989;59:954-958.

  20. Duffy SW, Tabar L, Chen HH, Holmquist M, Yen MF, Abdsalah S, et al. The impact of organized mammography service screening on breast carcinoma mortality in seven Swedish counties. Cancer 2002;95:458-469.

  21. American College of Radiology. Mammography Quality Control Manual. Reston: American College of Radiology, 1999.

  22. Perry N, Broeders M, de Wolf C, Tornberg S, Holland R, von Karsa L, et al., eds. European guidelines for quality assurance in breast cancer screening and diagnosis. Belgium: Office for Official Publications of the European Communities, 2005.

  23. Bihrmann K, Jensen A, Olsen AH, Njor S, Schwartz W, Vojborg T, et al. Performance of systematic and non-systematic (‘opportunistic’) screening mammography: a comparative study from Denmark. J Med Screen 2008;15:23-26.

  24. Boncz I, Sebestyen A, Pinter I, Battyany I, Ember I. The effect of an organized, nationwide breast cancer screening programme on nonorganized mammography activities. J Med Screen 2008;15:14-17.

  25. Vutuc C, Waldhoer T, Haidinger G. Breast cancer trends: opportunistic screening in Austria versus controlled screening in Finland and Sweden. Eur J Cancer Prev 2006;15:343-346.

  26. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.

  27. Wu GH, Chen LS, Chang KJ, et al. Evolution of breast cancer screening in countries with intermediate and increasing incidence of breast cancer. J Med Screen 2006;13 Suppl 1:S23-S27.

  28. Anderson BO, Yip CH, Smith RA, Shyyan R, Senor SF, Eniv A, et al. Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the Breast Health Global Initiative Global Summit 2007. Cancer 2008;113:2221-2243.

  29. Yip CH, Smith RA, Anderson BA, Miller AB, Thomas DB, Ang ES, et al. Guideline implementation for breast healthcare in low- and middleincome countries. Cancer 2008;113:2244-2256.

  30. Cazap E, Buzaid AC, Garbino C, de la Garza J, Orlandi FJ, Schwartsmann G, et al. Breast cancer in Latin America: results of the Latin American and Caribbean Society of Medical Oncology/Breast Cancer Research Foundation expert survey. Cancer 2008;113:2359-2365.

  31. Cazap E, Buzaid A, Garbino C, de la Garza J, Orlandi F, Schwartsmann G, et al. Breast cancer in Latin America: experts perceptions compared with medical care standards. Breast 2010;19:50-54.

  32. Lopez-Rios O, Lazcano-Ponce EC, Tovar-Guzman V, Hernandez-Avila M. La epidemia de cáncer de mama en México. ¿Consecuencias de la transición demográfica? Salud Publica Mex 1997;39:259-265.

  33. Franco-Marina F, Lazcano-Ponce E, Lopez-Carrillo L. Breast cancer mortality in Mexico: an age-period-cohort analysis. Salud Publica Mex 2009;51 Suppl 2:S157-S164.

  34. Palacio-Mejia LS, Lazcano-Ponce E, Allen-Leigh B, Hernandez-Avila M. Diferencias regionales en la mortalidad por cáncer de mama y cérvix en México entre 1979 y 2006. Salud Publica Mex 2009;51 Suppl 2:s208-s219.

  35. Knaul FM, Nigenda G, Lozano R, Arreola-Ornelas H, Langer A, Frenk J. Cáncer de mama en México: una prioridad apremiante. Salud Publica Mex 2009;51 Suppl 2:S335-S344.

  36. Mohar A, Bargallo E, Ramirez MT, Lara F, Beltran-Ortega A. Recursos disponibles para el tratamiento del cáncer de mama en México. Salud Publica Mex 2009;51 Suppl 2:S263-S269.

  37. Valencia-Mendoza A, Sanchez-Gonzalez G, Bautista-Arredondo S, Torres- Mejia G, Bertozzi SM. Costo-efectividad de políticas para el tamizaje de cáncer de mama en México. Salud Publica Mex 2009;51 Suppl 2:S296-S304.

  38. Rodriguez-Cuevas S, Guisa-Hohenstein F, Labastida-Almendaro S. First breast cancer mammography screening program in Mexico: initial results 2005-2006. Breast J 2009;15:623-631.

  39. Mittra I, Mishra GA, Singh S, Aranke S, Notani P, Badwe R, et al. A cluster randomized, controlled trial of breast and cervix cancer screening in Mumbai, India: methodology and interim results after three rounds of screening. Int J Cancer 2010;126:976-984.

  40. Pisani P, Parkin DM, Ngelangel C, Esteban D, Gibson L, Munson M, et al. Outcome of screening by clinical examination of the breast in a trial in the Philippines. Int J Cancer 2005.

  41. Lai MS, Yen MF, Kuo HS, Koong SL, Chen TH, Duffy SW. Efficacy of breastcancer screening for female relatives of breast-cancer-index cases: Taiwan multicentre cancer screening (TAMCAS). Int J Cancer 1998;78:21-26.

  42. Duffy SW, Tabar L, Smith RA, Krusemo UB, Prevost TC, Chen HH. Risk of breast cancer and risks with breast cancer: the relationship between histologic type and conventional risk factors, disease progression, and survival. Seminars in Breast Disease 1999.

  43. Stockton D, Davies T, Day N, McCann J. Retrospective study of reasons for improved survival in patients with breast cancer in east Anglia: earlier diagnosis or better treatment [published erratum appears in BMJ 1997 Mar 8;314(7082):721] [see comments]. Bmj 1997;314:472-475.

  44. Chu KC, Tarone RE, Kessler LG, Ries LA, Hankey BF, Miller BA, et al. Recent trends in U.S. breast cancer incidence, survival, and mortality rates [see comments]. J Natl Cancer Inst 1996;88:1571-1579.

  45. Menke CH, Pohlmann PR, Backes A, Cericatto R, Oliveira M, Bittelbrunn A, et al. Tumor size as a surrogate end point for the detection of early breast cancer: a 30-year (1972-2002), single-center experience in southern Brazil. Breast J 2007;13:448-456.

  46. Smith R. Commentary:Breast self examination: do we really know what we think we know? Bmj-USA 2003;3:168-169.

  47. Thomas DB, Gao DL, Ray RM, Wang WW, Allison CJ, Chen FL, et al. Randomized trial of breast self-examination in Shanghai: final results. J Natl Cancer Inst 2002;94:1445-1457.

  48. Fletcher SW, Elmore JG. Clinical practice. Mammographic screening for breas Berry DA. The utility of mammography for women aged 40 to 50 years (Con). In: De Vita VT, Hellman S, Rosenberg SA, eds. Progress in Oncology, 2002. Boston: Jones and Bartlett Publishers, 2003:346-372.

  49. Gotzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev 2006:CD001877.

  50. Esserman L, Shieh Y, Thompson I. Rethinking screening for breast cancer and prostate cancer. JAMA 2009;302:1685-1692.

  51. Nekhlyudov L, Ross-Degnan D, Fletcher SW. Beliefs and expectations of women under 50 years old regarding screening mammography: a qualitative study. J Gen Intern Med 2003;18:182-189.

  52. Elmore JG, Armstrong K, Lehman CD, Fletcher SW. Screening for breast cancer. JAMA 2005;293:1245-1256.

  53. Tabar L, Chen HH, Fagerberg G, Duffy SW, Smith TC. Recent results from the Swedish Two-County Trial: the effects of age, histologic type, and mode of detection on the efficacy of breast cancer screening. J Natl Cancer Inst Monogr 1997;22:43-47.

  54. Andersson I, Janzon L. Reduced breast cancer mortality in women under age 50: updated results from the Malmo Mammographic Screening Program. J Natl Cancer Inst Monogr 1997;22:63-67.

  55. Bjurstam N, Bjorneld L, Duffy SW, Smith TC, Cahlin E, Eriksson O, et al. The Gothenburg breast screening trial: first results on mortality, incidence, and mode of detection for women ages 39-49 years at randomization [see comments]. Cancer 1997;80:2091-2099.

  56. Moss SM, Cuckle H, Evans A, Johns L, Waller M, Bobrow L. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years’ follow-up: a randomised controlled trial. Lancet 2006;368:2053-2060.

  57. Coldman AJ, Major D, Doyle GP, D’Yachrova Y, Phillips N, Onysko, J, et al. Organized breast screening programs in Canada: effect of radiologist reading volumes on outcomes. Radiology 2006;238:809-815.

  58. Swedish Organized Service Screening Evaluation Group. Reduction in breast cancer mortality from organized service screening with mammography: 1. Further confirmation with extended data. Cancer Epidemiol Biomarkers Prev 2006;15:45-51.

  59. Swedish Organized Service Screening Evaluation Group. Effect of mammographic service screening on stage at presentation of breast cancers in Sweden. Cancer 2007;109:2205-2212.

  60. Gabe R, Duffy SW. Evaluation of service screening mammography in practice: the impact on breast cancer mortality. Ann Oncol 2005;16 Suppl 2:ii153-ii162.

  61. Sjonell G, Stahle L. Mammographic screening does not reduce breast cancer mortality. Lakartidningen 1999;96:8-13,904-905.

  62. Tabar L, Vitak B, Tony HH, Yen MF, Duffy SW, Smith RA. Beyond randomized controlled trials: organized mammographic screening substantially reduces breast carcinoma mortality. Cancer 2001;91: 1724-1731.

  63. Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res 2007;9:R28.

  64. Tabar L, Yen MF, Vitak B, Chen HH, Smith RA, Duffy SW. Mammography service screening and mortality in breast cancer patients: 20-year followup before and after introduction of screening. Lancet 2003;361:1405-1410.




2020     |     www.medigraphic.com